Skip to main content
Salma A. Bargal on Muck Rack

Salma A. Bargal

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Salma A.

Contact Salma A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses

|
By May E. Montasser, Salma A. Bargal, Elizabeth A. Streeten
| Wiley Online Library Verified
1 Introduction Sodium glucose cotransporter-2 (SGLT2) inhibitors are an important class of anti-diabetic drugs that provide substantial clinical benefits: HbA1c-lowering, weight loss, as well as cardiovascular (CV) and renal benefits [1-3], making them one of the most attractive add-on drug classes to treat type 2 diabetes (T2D).
Open in Who Shared Issue with article?

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy

|
By Nihal El Rouby, Christina L. Aquilante, Larisa H Cavallari, Salma A. Bargal
| Wiley Online Library Verified
1 Introduction Fluoropyrimidines, which include intravenous 5-fluorouracil (5-FU) and its oral prodrugs capecitabine and tegafur, are a vital component of chemotherapy regimens to treat various cancer types, with an estimated 2 million patients worldwide receiving a fluoropyrimidine each year [1, 2].
Open in Who Shared Issue with article?
See all 2 articles